简短引导式父母实施认知行为疗法与焦点解决短期疗法治疗儿童焦虑障碍的临床结局与成本效果:随机对照试验
该随机对照试验在英国牛津郡四家NHS儿童心理健康服务机构纳入136名5-12岁焦虑转诊儿童,比较简短引导式父母实施CBT与焦点解决短期疗法的临床结局和成本效果。
要点
- 两组临床改善率与QALY均无显著差异,无临床优效性证据。
- 父母实施CBT成本更低(均差-£448),可能具成本效果优势。
- 两组均未报告治疗相关或试验相关不良事件。
核心结论
- 简短引导式父母实施CBT与焦点解决短期疗法在临床结局上无显著差异,但前者成本更低,可能具成本效果优势,可考虑作为儿童焦虑问题的一线治疗选择。
研究设计与样本
- 随机对照试验,在英国牛津郡四家NHS初级儿童心理健康服务机构开展,纳入136名5-12岁焦虑转诊儿童,按1:1随机分配至简短引导式父母实施CBT组(n=68)或焦点解决短期疗法组(n=68),采用最小化法按年龄、性别、焦虑严重度和父母焦虑水平平衡,结果评估者盲法,意向性分析。
主要发现
- 两组均未报告治疗相关或试验相关不良事件。
关键数值与推荐
- 主要结局为基于临床总体印象改善量表(CGI-I)的康复;成本效用分析中的质量调整生命年(QALY)由Child Health Utility 9D推导;评估时间点为基线、治疗后(主要终点)和治疗完成后6个月。
临床怎么用
- 简短引导式父母实施CBT与焦点解决短期疗法临床效果相当,但前者成本更低,在资源有限时可优先考虑作为儿童焦虑问题的一线治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Half of all lifetime anxiety disorders emerge before age 12 years; however, access to evidence-based psychological therapies for affected children is poor. We aimed to compare the clinical outcomes and cost-effectiveness of two brief psychological treatments for children with anxiety referred to routine child mental health settings. We hypothesised that brief guided parent-delivered cognitive behavioural therapy (CBT) would be associated with better clinical outcomes than solution-focused brief therapy and would be cost-effective. METHODS: We did this randomised controlled trial at four National Health Service primary child and mental health services in Oxfordshire, UK. Children aged 5-12 years referred for anxiety difficulties were randomly allocated (1:1), via a secure online minimisation tool, to receive brief guided parent-delivered CBT or solution-focused brief therapy, with minimisation for age, sex, anxiety severity, and level of parental anxiety. The allocation sequence was not accessible to the researcher enrolling participants or to study assessors. Research staff who obtained outcome measurements were masked to group allocation and clinical staff who delivered the intervention did not measure outcomes. The primary outcome was recovery, on the basis of Clinical Global Impressions of Improvement (CGI-I). Parents recorded patient-level resource use. Quality-adjusted life-years (QALYs) for use in cost-utility analysis were derived from the Child Health Utility 9D. Assessments were done at baseline (before randomisation), after treatment (primary endpoint), and 6 months after treatment completion. We did analysis by intention to treat. This trial is registered with the ISCRTN registry, number ISRCTN07627865. FINDINGS: Between March 23, 2012, and March 31, 2014, we randomly assigned 136 patients to receive brief guided parent-delivered CBT (n=68) or solution-focused brief therapy (n=68). At the primary endpoint assessment (June, 2012, to September, 2014), 40 (59%) children in the brief guided parent-delivered CBT group versus 47 (69%) children in the solution-focused brief therapy group had an improvement of much or very much in CGI-I score, with no significant differences between groups in either clinical (CGI-I: relative risk 1·01, 95% CI 0·86-1·19; p=0·95) or economic (QALY: mean difference 0·006, -0·009 to 0·02; p=0·42) outcome measures. However, brief guided parent-delivered CBT was associated with lower costs (mean difference -£448; 95% CI -934 to 37; p=0·070) and, taking into account sampling uncertainty, was likely to represent a cost-effective use of resources compared with solution-focused brief therapy. No treatment-related or trial-related adverse events were reported in either group. INTERPRETATION: Our findings show no evidence of clinical superiority of brief guided parent-delivered CBT. However, guided parent-delivered CBT is likely to be a cost-effective alternative to solution-focused brief therapy and might be considered as a first-line treatment for children with anxiety problems. FUNDING: National Institute for Health Research.
引用
- Creswell C, Violato M, Fairbanks H, et al. Clinical outcomes and cost-effectiveness of brief guided parent-delivered cognitive behavioural therapy and solution-focused brief therapy for treatment of childhood anxiety disorders: a randomised controlled trial. Lancet Psychiatry. 2017. PMID: 28527657. doi:10.1016/S2215-0366(17)30149-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。